Research ArticleCancer

Patient-derived organoids can predict response to chemotherapy in metastatic colorectal cancer patients

See allHide authors and affiliations

Science Translational Medicine  09 Oct 2019:
Vol. 11, Issue 513, eaay2574
DOI: 10.1126/scitranslmed.aay2574

You are currently viewing the editor's summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution

Dishing out treatment recommendations

The number of treatment options for cancer patients keeps expanding, but it remains difficult to predict which tumors will be sensitive to which treatments. As a result, most patients receive treatment according to standardized protocols. With this approach, some patients respond to treatment, but others only experience side effects. To help address this situation, Ooft et al. developed a method of testing drugs in patient-derived organoids, biopsy-derived cells from individual patients grown in a dish. In a clinical study, the responses of organoids to irinotecan correlated with patients’ responses to the drug, suggesting that organoids could help avoid giving irinotecan to patients who would not benefit.

View Full Text